Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study.
Stella F, Chiappella A, Magni M, Bonifazi F, De Philippis C, Musso M, Cutini I, Ljevar S, Barbui AM, Farina M, Martino M, Massaia M, Grillo G, Angelillo P, Botto B, Patriarca F, Krampera M, Arcaini L, Tisi MC, Zinzani P, Sorà F, Bramanti S, Pennisi M, Carniti C, Corradini P. Stella F, et al. Among authors: bramanti s. Br J Haematol. 2024 Dec 22. doi: 10.1111/bjh.19961. Online ahead of print. Br J Haematol. 2024. PMID: 39710966
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study.
Chiappella A, Casadei B, Chiusolo P, Di Rocco A, Ljevar S, Magni M, Angelillo P, Barbui AM, Cutini I, Dodero A, Bonifazi F, Tisi MC, Bramanti S, Musso M, Farina M, Martino M, Novo M, Grillo G, Patriarca F, Zacchi G, Krampera M, Pennisi M, Galli E, Martelli M, Ferreri AJM, Ferrari S, Saccardi R, Bermema A, Guidetti A, Miceli R, Zinzani PL, Corradini P. Chiappella A, et al. Among authors: bramanti s. Leukemia. 2024 May;38(5):1107-1114. doi: 10.1038/s41375-024-02213-x. Epub 2024 Mar 8. Leukemia. 2024. PMID: 38459167 Free PMC article.
Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE study.
Barone A, Chiappella A, Casadei B, Bramanti S, Ljevar S, Chiusolo P, Di Rocco A, Tisi MC, Barbui AM, Farina M, Brunello L, Di Chio MC, Novo M, Musso M, Olivieri J, Trotta GE, Dodero A, Aiello A, Corradini P. Barone A, et al. Among authors: bramanti s. Br J Haematol. 2024 Oct;205(4):1356-1360. doi: 10.1111/bjh.19590. Epub 2024 Jun 15. Br J Haematol. 2024. PMID: 38877876 Free article.
Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas.
Dodero A, Bramanti S, Di Trani M, Pennisi M, Ljevar S, Chiappella A, Massimo M, Guidetti A, Corrado F, Nierychlewska PM, Di Rocco A, Lorenzini D, Daoud R, De Philippis C, Santoro A, Carlo-Stella C, Corradini P. Dodero A, et al. Among authors: bramanti s. Br J Haematol. 2024 Jan;204(1):151-159. doi: 10.1111/bjh.19057. Epub 2023 Sep 10. Br J Haematol. 2024. PMID: 37690811 Free article.
A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas.
Stella F, Chiappella A, Casadei B, Bramanti S, Ljevar S, Chiusolo P, Di Rocco A, Tisi MC, Carrabba MG, Cutini I, Martino M, Dodero A, Bonifazi F, Santoro A, Sorà F, Botto B, Barbui AM, Russo D, Musso M, Grillo G, Krampera M, Olivieri J, Ladetto M, Cavallo F, Massaia M, Arcaini L, Pennisi M, Zinzani PL, Miceli R, Corradini P. Stella F, et al. Among authors: bramanti s. Blood Cancer Discov. 2024 Sep 3;5(5):318-330. doi: 10.1158/2643-3230.BCD-24-0052. Blood Cancer Discov. 2024. PMID: 38953781 Free PMC article.
Out of specification Tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma.
De Philippis C, Zucchinetti C, Mannina D, Krampera M, Zinzani PL, Chiappella A, di Rocco A, Orcioulo E, Tisi MC, Pistolese F, Giordano L, Santoro A, Bramanti S. De Philippis C, et al. Among authors: bramanti s. Bone Marrow Transplant. 2024 Apr;59(4):569-571. doi: 10.1038/s41409-024-02205-6. Epub 2024 Jan 25. Bone Marrow Transplant. 2024. PMID: 38272998 No abstract available.
Multicenter Phase II Study on Haploidentical Bone Marrow Transplantation Using a Reduced-Intensity Conditioning Regimen and Posttransplantation Cyclophosphamide in Patients with Poor-Prognosis Lymphomas.
Castagna L, Dodero A, Patriarca F, Onida F, Olivieri A, Russo D, Giordano L, Majolino I, Bramanti S, Mariotti J, Sarina B, De Philippis C, Farina L, Carlo-Stella C, Corradini P, Santoro A. Castagna L, et al. Among authors: bramanti s. Transplant Cell Ther. 2021 Apr;27(4):328.e1-328.e6. doi: 10.1016/j.jtct.2021.01.007. Epub 2021 Jan 17. Transplant Cell Ther. 2021. PMID: 33836877 Free article. Clinical Trial.
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma.
Iacoboni G, Rejeski K, Villacampa G, van Doesum JA, Chiappella A, Bonifazi F, Lopez-Corral L, van Aalderen M, Kwon M, Martínez-Cibrian N, Bramanti S, Reguera-Ortega JL, Camacho-Arteaga L, Schmidt C, Marín-Niebla A, Kersten MJ, Martin Garcia-Sancho A, Zinzani PL, Corradini P, van Meerten T, Subklewe M, Barba P. Iacoboni G, et al. Among authors: bramanti s. Blood Adv. 2022 Jun 28;6(12):3606-3610. doi: 10.1182/bloodadvances.2021006922. Blood Adv. 2022. PMID: 35271707 Free PMC article. No abstract available.
141 results